Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies

Triple-negative breast cancer (TNBC) accounts for approximately 15%-20% of breast cancers diagnosed worldwide, which amounts to almost 200 000 cases each year. Although historically TNBC is considered difficult to treat with a poor prognosis, there is emerging evidence showing excellent response rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuhadra, Nour, Stecklein, Shane, Sharma, Priyanka, Moulder, Stacy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842325/
https://www.ncbi.nlm.nih.gov/pubmed/35305094
http://dx.doi.org/10.1093/oncolo/oyab003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842325/
https://www.ncbi.nlm.nih.gov/pubmed/35305094
http://dx.doi.org/10.1093/oncolo/oyab003

Ejemplares similares